Associate Professor, Medicine, University of Pittsburgh School of Medicine
Hematology
Dr. Gurkamal S. Chatta, MD
|
|
Give Review
Doctor Gurkamal S. Chatta, MD works in the field of Hematology. He received awards:"CMS Meaningful Use Stage 1 Certification". Dr. Gurkamal S. Chatta is also a published doctor. He has 48 paper published. The most recent paper is: T cells specific for a polymorphic segment of CD45 induce graft-versus-host disease with predominant pulmonary vasculitis. Doctor Gurkamal S. Chatta, MD is registered with Medicare and accepts Medicare payments.
Publications
- A phase II trial of dasatinib in patients with metastatic castration-resistant prostate Cancer treated previously with chemotherapy.
- A randomized, phase II study of pazopanib in castrate-sensitive prostate Cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clin...
- Phase II trial of bicalutamide in patients with advanced prostate Cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235).
- Intrathecal cytotoxic T-cell immunotherapy for metastatic leptomeningeal Melanoma.
- T cells specific for a polymorphic segment of CD45 induce graft-versus-host Disease with predominant pulmonary vasculitis.
- Identification of rat prostatic steroid-binding protein as a target antigen of experimental autoimmune prostatitis: implications for prostate Cancer therapy.
- In vivo effects of recombinant human granulocyte colony-stimulating factor on neutrophil oxidative functions in normal human volunteers.
- The effect on the insulin-like growth factor System in human prostate epithelial cells of immortalization and transformation by simian virus-40 T antigen.
- Aging and haemopoiesis. Implications for treatment with haemopoietic growth factors.
- Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans.
- Differential regulation of proto-oncogenes c-jun and c-fos in T lymphocytes activated through CD28.
- Hematopoietic progenitors and aging: alterations in granulocytic precursors and responsiveness to recombinant human G-CSF, GM-CSF, and IL-3.
- Effects of in vivo recombinant methionyl human granulocyte colony-stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy yo...
- Aging and marrow neutrophil reserves.
- [Tethered spinal cord and lipoma. Contribution of magnetic resonance imaging].
- Abnormal responsiveness of granulocyte-committed progenitor cells in cyclic neutropenia.
- Human renal cell carcinoma inhibits dendritic cell maturation and functions.
- Comparative Analysis of dendritic cells transduced with different anti-apoptotic molecules: sensitivity to tumor-induced apoptosis.
- Murine prostate Cancer inhibits both in vivo and in vitro generation of dendritic cells from bone marrow precursors.
- Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies?
- High dose calcitriol may reduce thrombosis in Cancer patients.
- NK cells mediate Flt3 ligand-induced protection of dendritic cell precursors in vivo from the inhibition by proState carcinoma in the murine bone marrow metastasis model.
- Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced Cancers.
- The AKT inhibitor perifosine in biochemically recurrent prostate Cancer: a phase II California/Pittsburgh Cancer consortium trial.
- Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicente...
- A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate Cancer: a California Cancer Consortium study.
- Oral fenretinide in biochemically recurrent prostate Cancer: a California Cancer consortium phase II trial.
- Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial Cancer, a California Cancer Consortium Trial.
- Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple Myeloma.
- Type-1 polarized dendritic cells loaded with apoptotic prostate Cancer cells are potent inducers of CD8(+) T cells against prostate Cancer cells and defined prostate c...
- Cancer chemotherapy in the elderly patient.
- A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate Cancer treated with intermittent androgen ablation.
- Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate Cancer.
- A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies.
- Intermittent chemotherapy in patients with metastatic androgen-independent prostate Cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose c...
- Inhibition of dendritic cell generation and function by serum from prostate Cancer patients: correlation with serum-free PSA.
- Dynamic alteration of soluble serum biomarkers in healthy aging.
- Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter ...
- Aging and the dendritic cell system: implications for Cancer.
- Adjuvant weekly docetaxel for patients with high risk prostate Cancer after radical prostatectomy: a multi-institutional pilot study.
- Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate Cancer: a report from the ...
- Inhibition of dendropoiesis by tumor derived and purified proState specific antigen.
- Restoration by IL-15 of MHC class I antigen-processing machinery in human dendritic cells inhibited by tumor-derived gangliosides.
- Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells c...
- Small rho GTPases regulate antigen presentation in dendritic cells.
- Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies.
- Regulation of dendritic cell expansion in aged athymic nude mice by FLT3 ligand.
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- View All
Doctors Specialties
- Geriatric Medicine
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Washington -
Delhi University College of Medical Sciences
Hospital
-
Roswell Park Cancer Institute
Drug Facts
| NPI NUMBER | 1114999083 | |
| NPPES Provider LastName | CHATTA | |
| NPPES Provider FirstName | GURKAMAL | |
| NPPES Provider ZIPCode | 152321301 | |
| NPPES Provider State | PA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 326.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 41.0 | |
| Percent Opioid Claims | 12.58 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1114999083 |
| Last Name Of The Provider | CHATTA |
| First Name Of The Provider | GURKAMAL |
| View All |
Similar Doctors
|
|
Dr. Emanuel E. Mamatas, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Douglas F. Clough, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Fredric W. Martin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Martin I. Seltman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Arshad I. Chughtai, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark S. Roberts, MD |
|
|
Dr. Elizabeth A. Mohan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Peter G. Ellis, MD |
|
|
Dr. Anthony R. Haradin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nathan Bahary, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert B. Kaplan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Rajiv Jain, MB |
|
|
Hideaki Tahara |